Estudi de la biodisponibilitat del quimiopreventiu del càncer de còlon trans

Estudi de la biodisponibilitat del
trans-resveratrol i el seu efecte
quimiopreventiu del càncer de còlon
induït per 1,2-dimetilhidrazina en rata
Irene Alfaras Cardenal
ADVERTIMENT. La consulta d’aquesta tesi queda condicionada a l’acceptació de les següents condicions d'ús: La difusió
d’aquesta tesi per mitjà del servei TDX (www.tdx.cat) ha estat autoritzada pels titulars dels drets de propietat intel·lectual
únicament per a usos privats emmarcats en activitats d’investigació i docència. No s’autoritza la seva reproducció amb
finalitats de lucre ni la seva difusió i posada a disposició des d’un lloc aliè al servei TDX. No s’autoritza la presentació del
seu contingut en una finestra o marc aliè a TDX (framing). Aquesta reserva de drets afecta tant al resum de presentació
de la tesi com als seus continguts. En la utilització o cita de parts de la tesi és obligat indicar el nom de la persona autora.
ADVERTENCIA. La consulta de esta tesis queda condicionada a la aceptación de las siguientes condiciones de uso: La
difusión de esta tesis por medio del servicio TDR (www.tdx.cat) ha sido autorizada por los titulares de los derechos de
propiedad intelectual únicamente para usos privados enmarcados en actividades de investigación y docencia. No se
autoriza su reproducción con finalidades de lucro ni su difusión y puesta a disposición desde un sitio ajeno al servicio
TDR. No se autoriza la presentación de su contenido en una ventana o marco ajeno a TDR (framing). Esta reserva de
derechos afecta tanto al resumen de presentación de la tesis como a sus contenidos. En la utilización o cita de partes de
la tesis es obligado indicar el nombre de la persona autora.
WARNING. On having consulted this thesis you’re accepting the following use conditions: Spreading this thesis by the
TDX (www.tdx.cat) service has been authorized by the titular of the intellectual property rights only for private uses placed
in investigation and teaching activities. Reproduction with lucrative aims is not authorized neither its spreading and
availability from a site foreign to the TDX service. Introducing its content in a window or frame foreign to the TDX service is
not authorized (framing). This rights affect to the presentation summary of the thesis as well as to its contents. In the using
or citation of parts of the thesis it’s obliged to indicate the name of the author.

VI. BIBLIOGRAFIA

VI. BIBLIOGRAFIA
127
Abd El-Mohsen, M., Bayele, H., Kuhnle, G., Gibson, G., Debnam, E., Kaila Srai, S., et al.
Distribution of [3H]trans-resveratrol in rat tissues following oral administration. Br. J. Nutr.
96 (1), 62-70, 2006.
Adachi, Y., Suzuki, H., Schinkel, A.H., Sugiyama, Y. Role of breast cancer resistance
protein (Bcrp1/Abcg2) in the extrusion of glucuronide and sulfate conjugates from
enterocytes to intestinal lumen. Mol. Pharmacol. 67 (3), 923-928, 2005.
Adesanya, S.A., Ogundana, S.K., Roberts, M.F. Dihydrostilbene phytoalexins from
Dioscorea bulbifera and D. dumentorum. Phytochemistry. 28 (3), 773-774, 1989.
Afaq, F., Adhami, V.M., Ahmad, N. Prevention of short-term ultraviolet B radiation-
mediated damages by resveratrol in SKH-1 hairless mice. Toxicol. Appl. Pharmacol. 186
(1), 28-37, 2003.
Aggarwal, B.B., Bhardwaj, A., Aggarwal, R.S., Seeram, N.P., Shishodia, S., Takada, Y.
Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies.
Anticancer Res. 24 (5A), 2783-2840, 2004.
Alfaras, I., Juan, M.E., Planas, J.M. trans-Resveratrol reduces precancerous colonic
lesions in dimethylhydrazine-treated rats. J. Agric. Food Chem. 58 (13), 8104-8110, 2010.
Alfaras, I., Pérez, M., Juan, M.E., Merino, G., Prieto, J.G., Planas, J.M., et al. Involvement
of breast cancer resistance protein (BCRP1/ABCG2) in the bioavailability and tissue
distribution of trans-resveratrol in knockout mice. J. Agric. Food Chem. 58 (7), 4523-4528,
2010.
Annese, V., Valvano, M.R., Palmieri, O., Latiano, A., Bossa, F., Andriulli, A. Multidrug
resistance 1 gene in inflammatory bowel disease: a meta-analysis. World J.
Gastroenterol. 12 (23), 3636-3644, 2006.
Arichi, H., Kimura, Y., Okuda, H., Bada, K., Kozawa, M., Arichi, S. Effects of stilbene
components of the roots of Polygonum cuspidatum Sieb. Et Zucc. on lipid metabolism.
Chem. Pharm. Bull. (Tokyo). 30 (5), 1766-1771, 1982.
Athar, M., Back, J.H., Kopelovich, L., Bickers, D.R., Kim, A.L. Multiple molecular targets of
resveratrol: Anti-carcinogenic mechanisms. Arch. Biochem. Biophys. 486 (2), 95-102,
2009.
Aziz, M., Kumar, R., Ahmad, N. Cancer chemopreventive by resveratrol: in vitro and in
vivo studies and the underlying mechanisms (Review). Int. J. Oncol. 23 (1), 17-28, 2003.

VI. BIBLIOGRAFIA
128
Balimane, P.V., Han, Y.H., Chong, S. Current industrial practices of assessing
permeability and P-glycoprotein interaction. AAPS J. 8 (1), E1-E13, 2006.
Banarjee, A., Johnston, J.S., Swaan, P.W. Carrier-mediated mechanisms for cellular drug
transport. A: Lu, D.R., Øie, S., editors. Cellular Drug Delivery: Principles and Practice.
New Jersey: Humana Press; 2004. p. 107-128.
Bass, T.M., Weinkove, D., Houthoofd, K., Gems, D., Partridge, L. Effects of resveratrol on
lifespan in Drosophila melanogaster and Caenorhabditis elegans. Mech. Ageing. Dev. 128
(10), 546-552, 2007.
Baur, J.A., Pearson, K.J., Price, N.L., Jamieson, H.A., Lerin, C., Kalra, A., et al.
Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 444
(7117), 337-342, 2006.
Baur, J.M. Resveratrol, sirtuins, and the promise of a DR mimetic. Mech. Ageing Dev. 131
(4), 261-269, 2010.
Baur, J.A., Sinclair, D.A. Therapeutic potential of resveratrol: the in vivo evidence. Nat
Rev Drug Discov. 5 (6), 493-506, 2006.
Belguendouz, L., Fremont, L., Linard, A. Resveratrol inhibits metal ion-dependent and
independent peroxidation of porcine low-density lipoproteins. Biochem. Pharmacol. 53 (9),
1347-1355, 1997.
Benedetti, M.S., Whomsley, R., Poggesi, I., Cawello, W., Mathy, F.X., Delporte, M.L., et
al. Drug metabolism and pharmacokinetics. Drug Metab. Rev. 41 (3), 344-390, 2009.
Bertelli, A.A., Das, D.K. Grapes, wines, resveratrol, and heart health. J. Cardiovasc.
Pharmacol. 54 (6), 468-476, 2009.
Bertelli, A.A., Gozzini, A., Stradi, R., Stella, S., Bertelli, A. Stability of resveratrol over time
and in the various stages of grape transformation. Drugs Exp. Clin. Res. 24 (4), 207-211,
1998.
Bird, R.P. Observation and quantification of aberrant crypts in the murine colon treated
with a colon carcinogen: preliminary findings. Cancer Lett. 37 (2), 147-151, 1987.
Bird, R.P. Role of aberrant crypt foci in understanding the pathogenesis of colon cancer.
Cancer Lett. 93 (1), 55-71, 1995.
Bisht, K., Wagner, K.H., Bulmer, A.C. Curcumin, resveratrol and flavonoids as anti-
inflammatory, cyto- and DNA-protective dietary compounds. Toxicology. 278 (1), 88-100,
2010.

VI. BIBLIOGRAFIA
129
Boocock, D.J., Patel, K.R., Faust, G.E., Normolle, D.P., Marczylo, T.H., Crowell, J.A., et
al. Quantitation of trans-resveratrol and detection of its metabolites in human plasma and
urine by high performance liquid chromatography. J. Chromatogr. B Analyt. Technol.
Biomed. Life Sci. 848 (2), 182-187, 2007.
Brisdelli, F., D'Andrea, G., Bozzi, A. Resveratrol: a natural polyphenol with multiple
chemopreventive properties. Curr. Drug Metab. 10 (6), 530-546, 2009.
Caderni, G., Femia, A.P., Gianninni, A., Favuzza, A., Luceri, C., Salvadori, M. et al.
Identification of mucin-depleted foci in the unsectioned colon of azoxymethane-treated
rats: correlation with carcinogenesis. Cancer Res. 63 (10), 2388-2392, 2003.
Caderni, G., Giannini, A., Lancioni, L., Luceri, C., Biggeri, A. i Dolara, P. Characterisation
of aberrant crypt foci in carcinogen-treated rats: association with intestinal carcinogenesis.
Br. J. Cancer. 71 (4), 763-769, 1995.
Campagna, M., Rivas, C. Antiviral activity of resveratrol. Biochem. Soc. Trans. 38 (Pt 1),
50-53, 2010.
Cano-Cebrián, M.J., Zornoza, T., Granero, L., Polache, A. Intestinal absorption
enhancement via the paracellular route by fatty acids, chitosans and others: a target for
drug delivery. Curr. Drug Deliv. 2 (1), 9-22, 2005.
Cao, Z., Li, Y. Potent induction of cellular antioxidants and phase 2 enzymes by
resveratrol in cardiomyocytes: protection against oxidative and electrophilic injury. Eur. J.
Pharmacol. 489 (1-2), 39-48, 2004.
Cardile, V., Lombardo, L., Spatafora, C., Tringali, C. Chemo-enzymatic synthesis and cell-
growth inhibition activity of resveratrol analogues. Bioorg. Chem. 33 (1), 22-33, 2005.
Casper, R.F., Quesme, M., Roqers, I.M., Shirota, T., Joliret, A., Milqrom, E., Savouret,
J.F. Resveratrol has antagonist activity on the aryl hydrocarbon receptor: implications for
prevention of dioxin toxicity. Mol. Pharmacol. 56 (4), 784-790, 1999.
Chan, L.M., Lowes, S., Hirst, B.H. The ABCs of drug transport in intestine and liver: efflux
proteins limiting drug absorption and bioavailability. Eur. J. Pharm. Sci. 21 (1), 25-51,
2004.
Chong, J., Poutaraud, A., Hugueney, P. Metabolism and roles of stilbenes in plants. Plant
Sci. 177 (3), 143-155, 2009.
Ciolino, H.P., Daschner, P.J., Yeh, G.C. Resveratrol inhibits transcription of CYP1A1 in
vitro by preventing activation of the aryl hydrocarbon receptor. Cancer Res. 58 (24), 5707-
5712, 1998.